Diabetes/Endocrine-Advanced Pharm Nursing

Diabetes/Endocrine-Advanced Pharm Nursing

Many patients, especially newly diagnosed patients, are prescribed medications that do not fit into the scheme of the ADA / AACE guidelines / best evidence based practices – for instance, starting on Januvia (sitagliptin) or Jardiance (empagliflozin) or Byetta (exenatide) as initial monotherapy. You know you’ve seen it happen.


In this discussion, please talk about how patients get put on these medications and why/how they should be transitioned to more evidence based treatments.

Is it ok to start a patient on a drug (particularly an oral drug) other than metformin as an initial drug? Please cite possible circumstances where this could be reasonable. Diabetes/Endocrine-Advanced Pharm Nursing
What anti-diabetic medications have compelling evidence for use in select populations and is this benefit a ”class” effect?
(eg. SGLT2Is – Patients with type 2 diabetes and a high risk of cardiovascular disease had reduced risk of a cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke relative to those randomized to receive placebo)
How can patients and practitioners be convinced to change their behavior and opt for more evidence based approach to therapy? Diabetes/Endocrine-Advanced Pharm Nursing

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top